Correspondence 0001104659-24-087378 from RIGEL PHARMACEUTICALS INC (RIGL) (CIK 0001034842) (RIGL)
RIGEL PHARMACEUTICALS INC (RIGL) (CIK 0001034842)
Date: Aug. 8, 2024 · CIK: 0001034842 · Accession: 0001104659-24-087378
AI Filing Summary & Sentiment
File numbers found in text: 333-281230
Letter
Rigel PHARMACEUTICALS, Inc.
611 Gateway Boulevard, Suite 900
South San Francisco, California 94080
(650) 624-1100
August 8, 2024
VIA EDGAR SUBMISSION
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Alan Campbell
Re:
Rigel Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-281230
Acceleration Request
Requested Date: August 9, 2024
Requested Time: 4:30 P.M., Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Rigel Pharmaceuticals, Inc. (the “Company”), hereby requests that the effective date of the Company’s Registration Statement on Form S-3, Registration Number 333-281230 (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:30 P.M., Eastern Time, on August 9, 2024, or as soon thereafter as practicable or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.
We would appreciate it if, as soon as the Registration Statement is declared effective, you would so inform Carlton Fleming of Sidley Austin LLP at (415) 772-1207.
Very truly yours,
/s/ Dean Schorno
Show Raw Text
CORRESP
1
filename1.htm
Rigel
PHARMACEUTICALS, Inc.
611 Gateway Boulevard,
Suite 900
South San Francisco,
California 94080
(650) 624-1100
August 8, 2024
VIA EDGAR SUBMISSION
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Alan Campbell
Re:
Rigel Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-281230
Acceleration Request
Requested Date: August 9, 2024
Requested Time: 4:30 P.M., Eastern Time
Ladies and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Rigel Pharmaceuticals, Inc. (the “Company”),
hereby requests that the effective date of the Company’s Registration Statement on Form S-3, Registration Number 333-281230
(the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become
effective at 4:30 P.M., Eastern Time, on August 9, 2024, or as soon thereafter as practicable or at such later time as the Company
or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange
Commission.
We would appreciate it
if, as soon as the Registration Statement is declared effective, you would so inform Carlton Fleming of Sidley Austin LLP at (415) 772-1207.
Very truly yours,
/s/ Dean Schorno
Dean Schorno
Chief Financial Officer
cc:
Carlton Fleming, Sidley Austin LLP